Single-domain antibody

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

Retrieved on: 
Monday, March 4, 2024
MIRA, University College Dublin, Doctor of Philosophy, MD, Teaching hospital, Single-domain antibody, EST, Hidradenitis suppurativa, Inflammation, AAD, Safety, Patient, PST, Moonlake, Venereology, HS, American Academy, Pharmaceutical industry

Kristian Reich, MD, PhD, Chief Scientific Officer at MoonLake commented: “We are pleased that the 24-week data from our Phase 2 MIRA trial has been selected by the American Academy of Dermatology as an oral late-breaking presentation.

Key Points: 
  • Kristian Reich, MD, PhD, Chief Scientific Officer at MoonLake commented: “We are pleased that the 24-week data from our Phase 2 MIRA trial has been selected by the American Academy of Dermatology as an oral late-breaking presentation.
  • The presentation will be held on Sunday 10 March at 14:00 PST / 17:00 EST / 23:00 CET during the late breaking research session 2 (S050) in room 20B.
  • Key members of the MoonLake team, including the executive leadership team, will attend AAD.
  • This was followed by an announcement in October 2023, reporting from the trial at 24 weeks, further establishing sonelokimab as a highly promising and differentiated therapeutic solution for HS.

Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug

Retrieved on: 
Monday, December 11, 2023
China Biologic Products, VHH, Aerosol, CDMO, Psoriasis, Antiviral Research, University Medical Center, Inflammation, Inhalation, COVID-19, Omicron, Infection, Antiviral drug, SARS-CoV-2, Max Planck Society, I&I, Single-domain antibody, Coronavirus, Arthritis, Weight loss, UMG, Vaccine, Pharmaceutical industry

JERUSALEM, Dec. 11, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (I&I) biological products, is pleased to announce the publication following peer-review of an article titled "Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters" in the prestigious scientific journal Antiviral Research.

Key Points: 
  • The Antiviral Research paper covers several aspects of the NanoAbs, including their structure, mechanism of action, neutralization of a wide range of SARS-CoV-2 variants including Omicron, production in yeast, and formulation into aerosols.
  • "Our next pipeline project is an anti-IL-17 NanoAb for the treatment of autoimmune diseases such as plaque psoriasis and psoriasis arthritis.
  • Amir Reichman, CEO of Scinai, added "The publication of this prestigious journal article comes at an auspicious time for our company.
  • It is currently undergoing copyediting and typesetting and will soon be updated with the final version at this same link.

IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.

Retrieved on: 
Tuesday, July 11, 2023
Reichmann, Infection, Asthma, Series, Interview, Macular degeneration, COVID-19, BVXV, Inflammation, Psoriasis, Patient, Autoimmune disease, Steroid, Podcast, Single-domain antibody, Interleukin, Letter, Max Planck Society, Humanitarian use licenses, IBN, Conditional sentence, Pharmaceutical industry

The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries.

Key Points: 
  • The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries.
  • Bell2Bell’s latest podcast features Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) .
  • To begin the latest interview, Reichman discussed the company’s recent achievements, as detailed in a letter to shareholders issued late last year.
  • The latest installment of The Bell2Bell Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series .

BioDuro-Sundia Wins Life Sciences Review Top 10 BPO Award

Retrieved on: 
Tuesday, April 4, 2023
Biotechnology, Manufacturing, Health, Pharmaceutical, Engineering, PROTAC, BPO, Business process, The Times Science Review, Interview, NASH, Drug discovery, Fine chemical, Single-domain antibody

Life Sciences Review magazine recognizes BioDuro-Sundia as a top 10 Business Process Outsourcing (BPO).

Key Points: 
  • Life Sciences Review magazine recognizes BioDuro-Sundia as a top 10 Business Process Outsourcing (BPO).
  • BioDuro-Sundia earned this award for its high-quality service and cutting-edge technology, as well as its integrated contract research, development and manufacturing (CRDMO) service platforms.
  • In an exclusive interview with Life Sciences Review magazine, Kent stated, “BioDuro-Sundia continues to make our customers a top priority.”
    "We have the largest privately held drug discovery platform.
  • “We are committed to enhance our offerings to better meet the continuously evolving needs of our clients.”
    Read the full article on Life Sciences Review website at: https://www.lifesciencesreview.com/biodurosundia .

BioDuro-Sundia Expands Drug Discovery Capacity and Capability

Retrieved on: 
Monday, February 13, 2023
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, NASH, Yahoo Beijing Global R&D Center, DEL, VHH, Discovery, DMPK, Growth, U.S. Postal Service Pro Cycling Team, PROTAC, Fine chemical, Single-domain antibody

BioDuro-Sundia has recently completed Discovery capability expansions of more than 100K ft2 of laboratory space within three different R&D Centers (Shanghai Waigaoqiao, Shanghai Zhangjiang, and Beijing).

Key Points: 
  • BioDuro-Sundia has recently completed Discovery capability expansions of more than 100K ft2 of laboratory space within three different R&D Centers (Shanghai Waigaoqiao, Shanghai Zhangjiang, and Beijing).
  • Dr. Xiang Li, President of BioDuro-Sundia Drug Discovery, explains: “At BioDuro-Sundia, we are fully invested in our clientele and pro-actively planning ahead to meet their needs.
  • All together, we substantially enhanced our capabilities and capacity to provide better services to our customers.
  • Some notable technology platforms developed at BioDuro-Sundia include PROTAC, Fragment-based drug discovery (FBDD), DNA-encoded library (DEL), Nanobody, NASH models etc.

Biocytogen Launches RenNano® Mouse, a Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery

Retrieved on: 
Thursday, January 5, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Neutralizing antibody, HKEX, Antigen, G protein-coupled receptor, Mouse, Traffic barrier, Drug development, Failure, VHH, Immunization, Risk, Shark, Animal, Medication, Tissue, Epitope, CAR, Single-domain antibody, Therapy, CDR3, Antibody, Human, Vaccine

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) officially launched its fully human heavy chain antibody platform, RenNano® .

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) officially launched its fully human heavy chain antibody platform, RenNano® .
  • Together, Biocytogen’s three RenMice™ platforms allow for the streamlined discovery and development of fully human monoclonal antibodies, bispecific/multispecific antibodies and single-domain antibodies (sdAbs, or nanobodies) (Figure 1).
  • To overcome these challenges, Biocytogen engineered the RenNano® mouse by modifying the constant region of the fully human RenMab™ model to allow for HCAb production.
  • The successful development of the RenNano® platform expands Biocytogen’s capabilities for antibody discovery and broadens the applications of our antibody library.

Biocytogen Launches RenNano™ Mouse, a Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery

Retrieved on: 
Friday, December 30, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Neutralizing antibody, HKEX, Antigen, G protein-coupled receptor, Mouse, Traffic barrier, Immunization, Drug development, Failure, VHH, Risk, Shark, Animal, Medication, Tissue, Epitope, Patient, CAR, Single-domain antibody, CDR3, Antibody, Human, Vaccine

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today officially launched its fully human heavy chain antibody platform, RenNano™.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today officially launched its fully human heavy chain antibody platform, RenNano™.
  • Together, Biocytogen’s three RenMice™ platforms allow for the streamlined discovery and development of fully human monoclonal antibodies, bispecific/multispecific antibodies and single-domain antibodies (sdAbs, or nanobodies).
  • Therefore, Biocytogen developed RenNano™ mouse that was engineered to produce HCAbs by modifying the constant region of the fully human RenMab™ model.
  • The successful development of the RenNano™ platform expands Biocytogen’s capabilities of antibody discovery and broadens the applications of our antibody library.

MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis

Retrieved on: 
Wednesday, December 14, 2022
Inflammatory arthritis, MIRA, PASI, Veni, vidi, vici, Security (finance), Psoriatic arthritis, Adalimumab, Fatigue, Health assessment, Severity, Ageing, Research, ACR, Psoriasis Area and Severity Index, American College of Rheumatology, Inflammation, American College, Safety, Skin, Pain, Chemokine, Disability, Psoriasis, Moonlake, Securities and Exchange Commission (Philippines), Quality of life, VHH, Temperature, Trial of the century, Joint, KDA, Disease, Tissue, Patient, Swelling, Single-domain antibody, Antibody, ARGO, Hidradenitis suppurativa, Pharmaceutical industry, Vaccine, Oyster, Medical imaging, Sanofi, Ablynx

Kristian Reich, Founder and Chief Scientific Officer at MoonLake, commented: “We are very pleased to have begun the ARGO study of the Nanobody sonelokimab in the treatment of psoriatic arthritis.

Key Points: 
  • Kristian Reich, Founder and Chief Scientific Officer at MoonLake, commented: “We are very pleased to have begun the ARGO study of the Nanobody sonelokimab in the treatment of psoriatic arthritis.
  • The study will comprise approximately 200 patients, and will evaluate different doses of sonelokimab, with placebo control and adalimumab as an active reference arm.
  • Sonelokimab has been assessed in a randomized, placebo-controlled Phase 2b study in 313 patients with moderate-to-severe plaque-type psoriasis.
  • Psoriatic arthritis (PsA) is a chronic and progressive inflammatory arthritis associated with psoriasis primarily affecting the peripheral joints.

IBN (InvestorBrandNetwork) Coverage Initiated for BiondVax Pharmaceuticals Ltd.

Retrieved on: 
Tuesday, December 6, 2022
Bristol Myers Squibb, R, Asthma, BVXV, Degenerative disease, VHH, IBN, University Medical Center, Single-domain antibody, GSK, News, Knowledge, MPG, Psoriasis, BiondVax, Social media, COVID-19, UMG, Pharmaceutical industry, Novartis

BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through in-house manufacturing to commercialization.

Key Points: 
  • BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through in-house manufacturing to commercialization.
  • As part of the Client Partner relationship, IBN will leverage its investor based distribution network of 5,000+ key syndication outlets , various newsletters , social media channels , wire services via InvestorWire , blogs and other outreach tools to generate greater awareness for BiondVax Pharmaceuticals .
  • IBN is uniquely positioned to provide BiondVax Pharmaceuticals the solutions needed to reach a wide audience of investors, journalists and the general public.
  • These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

USDA Scientists Produce Nanobodies in Plant Cells that Block Emerging Pathogens

Retrieved on: 
Wednesday, November 30, 2022
Degenerative disease, ARS, COVID-19, Science, Agricultural Research Service, Public health, Single-domain antibody, U.S. Department of Agriculture Cotton Annex, Plant, Agriculture, Neutralizing antibody, Research, Therapy, USDA, Animal, Severe acute respiratory syndrome coronavirus 2, Aquaculture

WASHINGTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Scientists at the U.S. Department of Agricultures (USDA) Agricultural Research Service (ARS) recently announced that plants could be used to produce nanobodies that quickly block emerging pathogens in human medicine and agriculture.

Key Points: 
  • WASHINGTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Scientists at the U.S. Department of Agricultures (USDA) Agricultural Research Service (ARS) recently announced that plants could be used to produce nanobodies that quickly block emerging pathogens in human medicine and agriculture.
  • ARS researchers turned to evaluating nanobodies to prevent and treat citrus greening disease in citrus trees.
  • These scientists are now using their newly developed and patented SymbiontTM technology to show that nanobodies can be easily produced in a plant system with broad agricultural and public health applications.
  • This cost-efficient, plant-based system proves that there are alternative ways to confront and prevent the spread of emerging pathogens.